Study With Vortioxetine on Emotional Functioning in Patients With Depression

PHASE4CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

February 5, 2019

Primary Completion Date

February 21, 2020

Study Completion Date

February 21, 2020

Conditions
Major Depressive Disorder
Interventions
DRUG

Vortioxetine

Flexible doses (10-20 mg) of vortioxetine; 10 mg during the first week which may be increased up to 20 mg week 2-8

Trial Locations (23)

Unknown

Office of Dr. Patrick Bourgoin (FR0011), Angoulême

Cabinet Psyche (FR0012), Douai

Centre Medical Ambroise Pare (FR0007), Élancourt

Dr. David Modavi Md, Office Of (FR0001), Toulouse

Private Practice Dr. Paule Khalifa (FR0010), Toulouse

GHS De Nancy - CPN Laxou (FR0006), Vandœuvre-lès-Nancy

Dr Karim Boutayeb MD, Office of (FR0009), Viersat

DSM Giulianova c/o ospedale di Giulianova (IT0004), Giulianova

Dipartimento Salute Mentale ASL Lecce (IT0006), Lecce

Universita degli Studi di Roma La Sapienza - Azienda Ospedaliera Sant Andrea (IT0013), Rome

JSC Romuvos Klinika (LT0002), Kaunas

Mental Health Centre Kaunas Outpatient Clinic (LT0005), Kaunas

JSC Nefridos klinika (LT0006), Klaipėda

Jsc Silutes Mental Health And Psychotherapy Center (LT0001), Šilutė

Antakalnis Psychiatric Consultation Centre (LT0003), Vilnius

PI Mental Health Center of Zirmunai (LT0004), Vilnius

Hospital Universitario Fundacion Alcorcon (ES0009), Alcorcón

Instituto Internacional de Neurociencias Aplicadas (ES0004), Barcelona

Centro De Salud Mental De Foios (ES0002), Foios

University of Oviedo (ES0011), Oviedo

Francesca Canellas Dols (ES0005), Palma de Mallorca

Hospital Clínico Universiatrio de Salamanca (ES0001), Salamanca

Centro De Especialidades A Doblada (ES0006), Vigo

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT03835715 - Study With Vortioxetine on Emotional Functioning in Patients With Depression | Biotech Hunter | Biotech Hunter